News Conference News ESC 2024 ‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS Michael O'Riordan September 09, 2024
News Daily News DES Best for In-Stent Restenosis, but DCBs Also Viable Michael O'Riordan August 13, 2024
News Conference News EAS 2023 Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1 Michael O'Riordan May 25, 2023
News Conference News EuroPCR 2023 ‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise Michael O'Riordan May 18, 2023
News Industry News TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism September 13, 2022
News Conference News TCT 2021 Good Long-term Results With FANTOM BVS, but More Data Needed Michael O'Riordan October 21, 2021
News Conference News EuroPCR 2019 Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements Shelley Wood May 16, 2019
News Conference News TCT 2018 Resolute Onyx Fares Well Against Thin-Strut Orsiro Stent in BIONYX All-Comers Study Michael O'Riordan September 22, 2018
News Conference News EuroPCR 2018 Chinese Firehawk Stent Performs Well Against Xience in All-Comers Study Michael O'Riordan May 29, 2018
News Daily News Uncomplicated TLR After PCI Linked With Worse Mortality Michael O'Riordan April 20, 2018
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2017 Shelley Wood November 29, 2017
News Conference News EuroPCR 2017 Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis Michael O'Riordan May 19, 2017
News Conference News TCT 2016 RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent Michael O'Riordan November 08, 2016
Presentation TCT 2016 RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso November 02, 2016
Presentation TCT 2016 FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Bo Xu October 31, 2016
Presentation TCT 2016 FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Antonio Colombo October 31, 2016
Presentation TCT 2016 MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth October 31, 2016
Presentation TCT 2016 FANTOM II: Six-Month and Nine-Month Clinical and Angiographic Results With a Radiopaque Desaminotyrosine Polycarbonate-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Alexandre Abizaid October 31, 2016
News Conference News TCT 2016 ‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent Michael O'Riordan October 30, 2016